FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886527406> ?p ?o ?g. }

• W2886527406 endingPage "17" @default.
• W2886527406 startingPage "1" @default.
• W2886527406 abstract "Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC). However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices. Nowadays, several companion diagnostic assays for PDL1 expression have been introduced for identifying patients who may benefit the immunotherapy. In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments, as compared to the monotherapy of these agents alone. In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for immunotherapy anti-PD-1/PDL1 antibodies. Of a great interest, potentials of the combinatory therapy of anti-PD-1/PDL1 therapy with a conventional or targeted therapy, or other immunotherapy such as CAR-T cell therapy were emphasized in the article." @default.
• W2886527406 created "2018-08-22" @default.
• W2886527406 creator A5008837341 @default.
• W2886527406 creator A5011424433 @default.
• W2886527406 creator A5018863416 @default.
• W2886527406 creator A5037979168 @default.
• W2886527406 creator A5048599640 @default.
• W2886527406 creator A5065859286 @default.
• W2886527406 creator A5087073672 @default.
• W2886527406 date "2018-08-08" @default.
• W2886527406 modified "2023-10-16" @default.
• W2886527406 title "Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies" @default.
• W2886527406 cites W1277869758 @default.
• W2886527406 cites W1489240871 @default.
• W2886527406 cites W1971821333 @default.
• W2886527406 cites W1982488143 @default.
• W2886527406 cites W1992839193 @default.
• W2886527406 cites W2010121426 @default.
• W2886527406 cites W2049553585 @default.
• W2886527406 cites W2050588414 @default.
• W2886527406 cites W2071865120 @default.
• W2886527406 cites W2095808484 @default.
• W2886527406 cites W2099674544 @default.
• W2886527406 cites W2101653483 @default.
• W2886527406 cites W2104347254 @default.
• W2886527406 cites W2110608569 @default.
• W2886527406 cites W2112680373 @default.
• W2886527406 cites W2123918574 @default.
• W2886527406 cites W2126427337 @default.
• W2886527406 cites W2131950300 @default.
• W2886527406 cites W2138619415 @default.
• W2886527406 cites W2143772132 @default.
• W2886527406 cites W2147592245 @default.
• W2886527406 cites W2156353875 @default.
• W2886527406 cites W2160834915 @default.
• W2886527406 cites W2175964092 @default.
• W2886527406 cites W2198093519 @default.
• W2886527406 cites W2253383790 @default.
• W2886527406 cites W2260067559 @default.
• W2886527406 cites W2288894747 @default.
• W2886527406 cites W2301488980 @default.
• W2886527406 cites W2329974159 @default.
• W2886527406 cites W2337507927 @default.
• W2886527406 cites W2342296008 @default.
• W2886527406 cites W2368001341 @default.
• W2886527406 cites W2464620827 @default.
• W2886527406 cites W2478967619 @default.
• W2886527406 cites W2509195076 @default.
• W2886527406 cites W2511190527 @default.
• W2886527406 cites W2512217706 @default.
• W2886527406 cites W2516652195 @default.
• W2886527406 cites W2521991465 @default.
• W2886527406 cites W2526084251 @default.
• W2886527406 cites W2528583885 @default.
• W2886527406 cites W2528861955 @default.
• W2886527406 cites W2529904548 @default.
• W2886527406 cites W2560367415 @default.
• W2886527406 cites W2560704457 @default.
• W2886527406 cites W2562305489 @default.
• W2886527406 cites W2570618306 @default.
• W2886527406 cites W2572174216 @default.
• W2886527406 cites W2574398598 @default.
• W2886527406 cites W2588781634 @default.
• W2886527406 cites W2589004473 @default.
• W2886527406 cites W2589103622 @default.
• W2886527406 cites W2589171490 @default.
• W2886527406 cites W2591943527 @default.
• W2886527406 cites W2594102731 @default.
• W2886527406 cites W2601596971 @default.
• W2886527406 cites W2604893395 @default.
• W2886527406 cites W2604982880 @default.
• W2886527406 cites W2606022415 @default.
• W2886527406 cites W2606523512 @default.
• W2886527406 cites W2610224116 @default.
• W2886527406 cites W2611896937 @default.
• W2886527406 cites W2613260339 @default.
• W2886527406 cites W2613324349 @default.
• W2886527406 cites W2619078406 @default.
• W2886527406 cites W2622499649 @default.
• W2886527406 cites W2622595542 @default.
• W2886527406 cites W2623285630 @default.
• W2886527406 cites W2623388110 @default.
• W2886527406 cites W2624310346 @default.
• W2886527406 cites W2625684877 @default.
• W2886527406 cites W2676895855 @default.
• W2886527406 cites W2728734704 @default.
• W2886527406 cites W2736039453 @default.
• W2886527406 cites W2745683917 @default.
• W2886527406 cites W2753065806 @default.
• W2886527406 cites W2754479248 @default.
• W2886527406 cites W2754562255 @default.
• W2886527406 cites W2758701828 @default.
• W2886527406 cites W2765696340 @default.
• W2886527406 cites W2765753235 @default.
• W2886527406 cites W2765943070 @default.
• W2886527406 cites W2766342472 @default.
• W2886527406 cites W2766425839 @default.
• W2886527406 cites W2767570960 @default.

• next